Arterial and venous thromboembolic events during anti-TNF therapy: A study of 85 spontaneous reports in the period 2000–2006
Bio-Medical Materials and Engineering2009Vol. 19(4-5), pp. 355–364
Citations Over TimeTop 10% of 2009 papers
Nadine Petitpain, Nicolas Gambier, Denis Wahl, Isabelle Chary-Valckenaere, Damien Lœuille, Pierre Gillet
Abstract
Despite its limitations, this study suggests that venous TE could be favoured by TNF-alpha blockers therapy since they occurred in patients with no or few risk factors for venous thrombosis. However, this needs to be more evaluated by controlled studies.
Related Papers
- → Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry(2015)12 cited
- → Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis(2014)9 cited
- → Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: A case series(2010)18 cited
- → SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB(2017)14 cited
- → Adalimumab and etanercept adherence, persistence and switch in the treatment of psoriatic arthritis: 10-year real-life analysis(2019)8 cited